Inflammation Mediated Hepcidin-Ferroportin Pathway and Its Therapeutic Window in Breast Cancer

References

• Collaborators GRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England). 2016;388(10053):1659.
   Web of Science ®Google Scholar
• SiegelRL, KimberlyD, MillerM, et al. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• ChekhunVF, LukyanovaNY, BurlakaАP, et al. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int J Oncol. 2013;43(5):1481–1486. doi:10.3892/ijo.2013.206323969999
   PubMed Web of Science ®Google Scholar
• ScimecaM, BonannoE. New highlight in breast cancer development: the key role of hepcidin and iron metabolism. Ann Transl Med. 2018;6(Suppl):1.29404347
   PubMed Web of Science ®Google Scholar
• AlarmoE-L, KallioniemiA. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?Endocr Relat Cancer. 2010;17(2):R123–R139. doi:10.1677/ERC-09-027320335308
   PubMed Web of Science ®Google Scholar
• MiguelF, LopesLV, FerreiraE, et al. Breast cancer in Angola, molecular subtypes: a first glance. ecancermedicalscience. 2017;11.
   Google Scholar
• AdeloyeD, SowunmiOY, JacobsW, et al. Estimating the incidence of breast cancer in Africa: a systematic review and meta-analysis. J Glob Health. 2018;8:1. doi:10.7189/jogh.08.010419
   Web of Science ®Google Scholar
• AzubuikeSO, MuirheadC, HayesL, et al. Rising global burden of breast cancer: the case of sub-Saharan Africa (with emphasis on Nigeria) and implications for regional development: a review. World J Surg Oncol. 2018;16(1):1–13. doi:10.1186/s12957-018-1345-229291744
   PubMed Web of Science ®Google Scholar
• YuY, KovacevicZ, RichardsonDR. Tuning cell cycle regulation with an iron key. Cell Cycle. 2007;6(16):1982–1994. doi:10.4161/cc.6.16.460317721086
   PubMed Web of Science ®Google Scholar
• AndersonCP, ShenM, EisensteinRS, et al. Mammalian iron metabolism and its control by iron regulatory proteins. Biochimica Et Biophysica Acta Mol Cell Res. 2012;1823(9):1468–1483. doi:10.1016/j.bbamcr.2012.05.010
   PubMed Web of Science ®Google Scholar
• VermaS, CherayilBJ. Iron and inflammation–the gut reaction. Metallomics. 2017;9(2):101–111. doi:10.1039/C6MT00282J28067386
   PubMed Web of Science ®Google Scholar
• YiannikouridesA, Latunde-DadaGO. A short review of iron metabolism and pathophysiology of iron disorders. Medicines. 2019;6(3):85.
   Google Scholar
• JungM, MertensC, TomatE, et al. Iron as a central player and promising target in cancer progression. Int J Mol Sci. 2019;20(2):273. doi:10.3390/ijms20020273
   PubMed Web of Science ®Google Scholar
• ChangVC, CotterchioM, KhooE. Iron intake, body iron status, and risk of breast cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):543. doi:10.1186/s12885-019-5642-031170936
   PubMed Web of Science ®Google Scholar
• HuangX. Does iron have a role in breast cancer?Lancet Oncol. 2008;9(8):803–807. doi:10.1016/S1470-2045(08)70200-618672216
   PubMed Web of Science ®Google Scholar
• HechtF, PessoaCF, GentileLB, et al. The role of oxidative stress on breast cancer development and therapy. Tumor Biol. 2016;37(4):4281–4291. doi:10.1007/s13277-016-4873-9
   PubMedGoogle Scholar
• ChifmanJ, AratS, DengZ, et al. Activated oncogenic pathway modifies Iron network in breast epithelial cells: a dynamic modeling perspective. PLoS Comput Biol. 2017;13(2):e1005352. doi:10.1371/journal.pcbi.100535228166223
   PubMed Web of Science ®Google Scholar
• PantopoulosK, PorwalSK, TartakoffA, et al. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012;51(29):5705–5724. doi:10.1021/bi300752r22703180
   PubMed Web of Science ®Google Scholar
• SoysalSD, TzankovA, MuenstSE. Role of the tumor microenvironment in breast cancer. Pathobiology. 2015;82(3–4):142–152. doi:10.1159/00043049926330355
   PubMed Web of Science ®Google Scholar
• AllenMD, JonesLJ. The role of inflammation in progression of breast cancer: friend or foe?Int J Oncol. 2015;47(3):797–805. doi:10.3892/ijo.2015.307526165857
   PubMed Web of Science ®Google Scholar
• PlaceAE, HuhSJ, PolyakK. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13(6):1–11. doi:10.1186/bcr2912
   Web of Science ®Google Scholar
• ManzDH, BlanchetteNL, PaulBT, et al. Iron and cancer: recent insights. Ann N Y Acad Sci. 2016;1368(1):149. doi:10.1111/nyas.1300826890363
   PubMed Web of Science ®Google Scholar
• RichardsonDR, LaneDJ, BeckerEM, et al. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci. 2010;107(24):10775–10782. doi:10.1073/pnas.091292510720495089
   PubMed Web of Science ®Google Scholar
• ZhouL, ZhaoB, ZhangL, et al. Alterations in cellular iron metabolism provide more therapeutic opportunities for cancer. Int J Mol Sci. 2018;19(5):1545. doi:10.3390/ijms19051545
   PubMed Web of Science ®Google Scholar
• AndrewsNC, SchmidtPJ. Iron homeostasis. Annu Rev Physiol. 2007;69:69–85. doi:10.1146/annurev.physiol.69.031905.16433717014365
   PubMed Web of Science ®Google Scholar
• McKieAT, BarrowD, Latunde-DadaGO, et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science. 2001;291(5509):1755–1759. doi:10.1126/science.105720611230685
   PubMed Web of Science ®Google Scholar
• ChenY, FanZ, YangY, et al. Iron metabolism and its contribution to cancer. Int J Oncol. 2019;54(4):1143–1154.30968149
   PubMed Web of Science ®Google Scholar
• WangJ, PantopoulosK. Regulation of cellular iron metabolism. Biochem J. 2011;434(3):365–381.21348856
   PubMed Web of Science ®Google Scholar
• AbbaspourN, HurrellR, KelishadiR. Review on iron and its importance for human health. J Res Med Sci. 2014;19(2):164.24778671
   PubMed Web of Science ®Google Scholar
• BafaroE, LiuY, XuY, et al. The emerging role of zinc transporters in cellular homeostasis and cancer. Signal Transduction Targeted Ther. 2017;2(1):1–12.
   Web of Science ®Google Scholar
• LaneD, MerlotA, HuangM-H, et al. Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease. Biochimica Et Biophysica Acta Mol Cell Res. 2015;1853(5):1130–1144. doi:10.1016/j.bbamcr.2015.01.021
   PubMed Web of Science ®Google Scholar
• JenkitkasemwongS, WangC-Y, MackenzieB, et al. Physiologic implications of metal-ion transport by ZIP14 and ZIP8. Biometals. 2012;25(4):643–655. doi:10.1007/s10534-012-9526-x22318508
   PubMed Web of Science ®Google Scholar
• TortiFM, TortiSV. Regulation of ferritin genes and protein. Blood J Am Soc Hematol. 2002;99(10):3505–3516.
   Google Scholar
• PinnixZK, MillerLD, WangW, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010;2(43):43ra56–43ra56. doi:10.1126/scitranslmed.3001127
   PubMed Web of Science ®Google Scholar
• TortiSV, TortiFM. Ironing out cancer. Cancer Res. 2011;71(5):1511–1514. doi:10.1158/0008-5472.CAN-10-361421363917
   PubMed Web of Science ®Google Scholar
• GuoW, ZhangS, ChenY, et al. An important role of the hepcidin–ferroportin signaling in affecting tumor growth and metastasis. Acta Biochim Biophys Sin (Shanghai). 2015;47(9):703–715. doi:10.1093/abbs/gmv06326201356
   PubMed Web of Science ®Google Scholar
• AbboudS, HaileDJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275(26):19906–19912. doi:10.1074/jbc.M00071320010747949
   PubMed Web of Science ®Google Scholar
• MuckenthalerMU, RivellaS, HentzeMW, et al. A red carpet for iron metabolism. Cell. 2017;168(3):344–361. doi:10.1016/j.cell.2016.12.03428129536
   PubMed Web of Science ®Google Scholar
• HentzeMW, MuckenthalerMU, GalyB, et al. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142(1):24–38. doi:10.1016/j.cell.2010.06.02820603012
   PubMed Web of Science ®Google Scholar
• HamdiA, RoshanTM, KahawitaTM, et al. Erythroid cell mitochondria receive endosomal iron by a “kiss-and-run” mechanism. Biochimica Et Biophysica Acta (BBA)-Molecular Cell Research. 2016;1863(12):2859–2867. doi:10.1016/j.bbamcr.2016.09.00827627839
   PubMed Web of Science ®Google Scholar
• WestAP, BennettMJ, SellersVM, et al. Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE. J Biol Chem. 2000;275(49):38135–38138. doi:10.1074/jbc.C00066420011027676
   PubMed Web of Science ®Google Scholar
• KawabataH, GermainRS, VuongPT, et al. Transferrin receptor 2-α supports cell growth both in iron-chelated cultured cells and in vivo. J Biol Chem. 2000;275(22):16618–16625. doi:10.1074/jbc.M90884619910748106
   PubMed Web of Science ®Google Scholar
• ChengY, ZakO, AisenP, et al. Structure of the human transferrin receptor-transferrin complex. Cell. 2004;116(4):565–576. doi:10.1016/S0092-8674(04)00130-814980223
   PubMed Web of Science ®Google Scholar
• GaussGH, KlevenMD, SendamaraiAK, et al. The crystal structure of six-transmembrane epithelial antigen of the prostate 4 (Steap4), a ferri/cuprireductase, suggests a novel interdomain flavin-binding site. J Biol Chem. 2013;288(28):20668–20682. doi:10.1074/jbc.M113.47915423733181
   PubMed Web of Science ®Google Scholar
• OhgamiRS, CampagnaDR, McDonaldA, et al. The Steap proteins are metalloreductases. Blood. 2006;108(4):1388–1394. doi:10.1182/blood-2006-02-00368116609065
   PubMed Web of Science ®Google Scholar
• WrightingDM, AndrewsNC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204–3209. doi:10.1182/blood-2006-06-02763116835372
   PubMed Web of Science ®Google Scholar
• ZhaoN, ZhangA-S, EnnsCA. Iron regulation by hepcidin. J Clin Invest. 2013;123(6):2337–2343.23722909
   PubMed Web of Science ®Google Scholar
• NemethE, GanzT. Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 2006;26:323–342. doi:10.1146/annurev.nutr.26.061505.11130316848710
   PubMed Web of Science ®Google Scholar
• GanzT, NemethE. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Prog. 2011;2011(1):538–542.
   Web of Science ®Google Scholar
• Subha PalaneeswariM, GaneshM, KarthikeyanT, et al. Hepcidin–Minireview. J Clin Diagnostic Res. 2013;7(8):1767.
   Google Scholar
• MaesK, NemethE, RoodmanGD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood J Am Soc Hematol. 2010;116(18):3635–3644.
   Google Scholar
• WuX, YungL-M, ChengW-H, et al. Hepcidin regulation by BMP signaling in macrophages is lipopolysaccharide dependent. PLoS One. 2012;7(9):e44622. doi:10.1371/journal.pone.004462223028567
   PubMed Web of Science ®Google Scholar
• TruksaJ, PengH, LeeP, et al. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci. 2006;103(27):10289–10293. doi:10.1073/pnas.060312410316801541
   PubMed Web of Science ®Google Scholar
• ZhangA-S. Control of systemic iron homeostasis by the hemojuvelin-hepcidin axis. Advan Nutri. 2010;1(1):38–45. doi:10.3945/an.110.1009
   Web of Science ®Google Scholar
• CamaschellaC, NaiA, SilvestriL. Iron metabolism and iron disorders revisited in the hepcidin era. haematologica. 2020;105(2):260–272. doi:10.3324/haematol.2019.23212431949017
   PubMed Web of Science ®Google Scholar
• WangC-Y, CoreAB, CanaliS, et al. Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice. Blood J Am Soc Hematol. 2017;130(1):73–83.
   Google Scholar
• CasanovasG, BanerjiA, d’AlessioF, et al. A multi-scale model of hepcidin promoter regulation reveals factors controlling systemic iron homeostasis. PLoS Comput Biol. 2014;10(1):e1003421. doi:10.1371/journal.pcbi.100342124391488
   PubMed Web of Science ®Google Scholar
• CasanovasG, Mleczko-SaneckaK, AltamuraS, et al. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med. 2009;87(5):471–480. doi:10.1007/s00109-009-0447-219229506
   PubMed Web of Science ®Google Scholar
• ImamMU, ZhangS, MaJ, et al. Antioxidants mediate both iron homeostasis and oxidative stress. Nutrients. 2017;9(7):671. doi:10.3390/nu9070671
   PubMed Web of Science ®Google Scholar
• Fustinoni-ReisAM, ArrudaSF, DouradoLP, et al. Tucum-do-cerrado (Bactris setosa Mart.) consumption modulates iron homeostasis and prevents iron-induced oxidative stress in the rat liver. Nutrients.2016;8(2):38.26901220
   PubMed Web of Science ®Google Scholar
• Fischer-FodorE, MiklasovaN, Berindan-NeagoeI, et al. Iron, inflammation and invasion of cancer cells. Clujul Med. 2015;88(3):272.26609256
   PubMedGoogle Scholar
• De DomenicoI, WardDM, LangelierC, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell. 2007;18(7):2569–2578. doi:10.1091/mbc.e07-01-006017475779
   PubMed Web of Science ®Google Scholar
• ZhangS, ChenY, GuoW, et al. Disordered hepcidin–ferroportin signaling promotes breast cancer growth. Cell Signal. 2014;26(11):2539–2550. doi:10.1016/j.cellsig.2014.07.02925093806
   PubMed Web of Science ®Google Scholar
• GanzT. Erythropoietic regulators of iron metabolism. Free Radic Biol Med. 2019;133:69–74. doi:10.1016/j.freeradbiomed.2018.07.00329981834
   PubMed Web of Science ®Google Scholar
• WangY, YuL, DingJ, et al. Iron metabolism in cancer. Int J Mol Sci. 2019;20(1):95. doi:10.3390/ijms20010095
   Web of Science ®Google Scholar
• KautzL, JungG, ValoreEV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–684. doi:10.1038/ng.299624880340
   PubMed Web of Science ®Google Scholar
• ZhangJ, ChenX. p53 tumor suppressor and iron homeostasis. FEBS J. 2019;286(4):620–629. doi:10.1111/febs.1463830133149
   PubMed Web of Science ®Google Scholar
• SchmidtPJ. Regulation of iron metabolism by hepcidin under conditions of inflammation. J Biol Chem. 2015;290(31):18975–18983. doi:10.1074/jbc.R115.65015026055723
   PubMed Web of Science ®Google Scholar
• TortiSV, TortiFM. Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncogenesis. 2013;18:5. doi:10.1615/CritRevOncog.2013007784
   Google Scholar
• HawulaZJ, WallaceDF, SubramaniamVN, et al. Therapeutic advances in regulating the hepcidin/ferroportin axis. Pharmaceuticals. 2019;12(4):170. doi:10.3390/ph12040170
   Web of Science ®Google Scholar
• RausaM, GhittiM, PaganiA, et al. Identification of TMPRSS 6 cleavage sites of hemojuvelin. J Cell Mol Med. 2015;19(4):879–888. doi:10.1111/jcmm.1246225704252
   PubMed Web of Science ®Google Scholar
• MeynardD, VajaV, SunCC, et al. Regulation of TMPRSS6 by BMP6 and iron in human cells and mice. Blood J Am Soc Hematol. 2011;118(3):747–756.
   Google Scholar
• LakhalS, SchödelJ, TownsendAR, et al. Regulation of Type II transmembrane serine proteinase TMPRSS6 by Hypoxia-inducible Factors new link Between Hypoxia Signaling And Iron Homeostasis. J Biol Chem. 2011;286(6):4090–4097. doi:10.1074/jbc.M110.17309620966077
   PubMed Web of Science ®Google Scholar
• LuoM, ShangL, BrooksMD, et al. Targeting breast cancer stem cell state equilibrium through modulation of redox signaling. Cell Metab. 2018;28(1):69–86. e66. doi:10.1016/j.cmet.2018.06.00629972798
   PubMed Web of Science ®Google Scholar
• TortiSV, ManzDH, PaulBT, et al. Iron and cancer. Annu Rev Nutr. 2018;38:97–125. doi:10.1146/annurev-nutr-082117-05173230130469
   PubMed Web of Science ®Google Scholar
• SaneelaS, IqbalR, RazaA, et al. Hepcidin: a key regulator of iron. J Pak Med Assoc. 2019;69(8):1170–1175.31431773
   PubMed Web of Science ®Google Scholar
• VelaD, Vela-GaxhaZ. Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications. Exp Mol Med. 2018;50(2):e436–e436. doi:10.1038/emm.2017.27329391539
   PubMed Web of Science ®Google Scholar
• ChanS, ChenJ-H, LiS, et al. Evaluation of the association between quantitative mammographic density and breast cancer occurred in different quadrants. BMC Cancer. 2017;17(1):274. doi:10.1186/s12885-017-3270-028415974
   PubMed Web of Science ®Google Scholar
• OnitiloAA, EngelJM, GreenleeRT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1–2):4–13. doi:10.3121/cmr.2008.82519574486
   PubMedGoogle Scholar
• XuanQ-J, WangJ-X, NandingA, et al. Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients. Pathol Oncol Res. 2014;20(3):619–624. doi:10.1007/s12253-013-9740-z24414992
   PubMed Web of Science ®Google Scholar
• ShaoX, CaoF, TaoM. The clinical value of hepcidin in breast cancer and its bone metastasis. Ann Clin Lab Sci. 2017;47(2):120–128.28442512
   PubMed Web of Science ®Google Scholar
• SunX-H, CaoQ, XiaoJ-Y. Clinical significance of serum tumor markers and cytokines in the detection of breast cancer. J Hainan Med Univ. 2017;23(2):61–64.
   Google Scholar
• MaoY, KellerET, GarfieldDH, et al. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013;32(1–2):303–315. doi:10.1007/s10555-012-9415-323114846
   PubMed Web of Science ®Google Scholar
• ObeidE, NandaR, FuY-X, et al. The role of tumor-associated macrophages in breast cancer progression. Int J Oncol. 2013;43(1):5–12. doi:10.3892/ijo.2013.193823673510
   PubMed Web of Science ®Google Scholar
• JeongH, HwangI, KangSH, et al. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer. 2019;22(1):38–51. doi:10.4048/jbc.2019.22.e530941232
   PubMed Web of Science ®Google Scholar
• MahmoudS, LeeA, PaishE, et al. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2012;65(2):159–163. doi:10.1136/jclinpath-2011-20035522049225
   PubMed Web of Science ®Google Scholar
• PohAR, ErnstM. Targeting macrophages in cancer: from bench to bedside. Front Oncol. 2018;8:49. doi:10.3389/fonc.2018.0004929594035
   PubMed Web of Science ®Google Scholar
• QiuS-Q, WaaijerSJ, ZwagerMC, et al. Tumor-associated macrophages in breast cancer: innocent bystander or important player?Cancer Treat Rev. 2018;70:178–189. doi:10.1016/j.ctrv.2018.08.01030227299
   PubMed Web of Science ®Google Scholar
• MukhtarRA, NseyoO, CampbellMJ, et al. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011;11(1):91–100. doi:10.1586/erm.10.9721171924
   PubMed Web of Science ®Google Scholar
• MasjediA, HashemiV, Hojjat-FarsangiM, et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother. 2018;108:1415–1424. doi:10.1016/j.biopha.2018.09.17730372844
   PubMed Web of Science ®Google Scholar
• CairoG, RecalcatiS, MantovaniA, et al. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 2011;32(6):241–247. doi:10.1016/j.it.2011.03.00721514223
   PubMed Web of Science ®Google Scholar
• SanguinettiA, SantiniD, BonafèM, et al. Interleukin-6 and pro inflammatory status in the breast tumor microenvironment. World J Surg Oncol. 2015;13(1):129. doi:10.1186/s12957-015-0529-225881039
   PubMed Web of Science ®Google Scholar
• HamS, LimaLG, ChaiEPZ, et al. Breast cancer-derived exosomes alter macrophage polarization via gp130/STAT3 signaling. Front Immunol. 2018;9:871. doi:10.3389/fimmu.2018.0087129867925
   PubMed Web of Science ®Google Scholar
• Verga FalzacappaMV, Vujic SpasicM, KesslerR, et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109(1):353–358. doi:10.1182/blood-2006-07-03396916946298
   PubMed Web of Science ®Google Scholar
• ConzeD, WeissL, RegenPS, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001;61(24):8851–8858.11751408
   PubMed Web of Science ®Google Scholar
• KnüpferH, PreißR. Significance of interleukin-6 (IL-6) in breast cancer. Breast Cancer Res Treat. 2007;102(2):129–135. doi:10.1007/s10549-006-9328-316927176
   PubMed Web of Science ®Google Scholar
• CiniselliCM, De BortoliM, TavernaE, et al. Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone. Expert Rev Proteomics. 2015;12(6):695–701. doi:10.1586/14789450.2015.109943626496240
   PubMed Web of Science ®Google Scholar
• PaukM, GrgurevicL, BrkljacicJ, et al. Exogenous BMP7 corrects plasma iron overload and bone loss in Bmp6-/-mice. Int Orthop. 2015;39(1):161–172. doi:10.1007/s00264-014-2550-425300398
   PubMed Web of Science ®Google Scholar
• Pfeifhofer-ObermairC, TymoszukP, PetzerV, et al. Iron in the tumor microenvironment—connecting the dots. Front Oncol. 2018;8:549.30534534
   PubMed Web of Science ®Google Scholar
• OrlandiR, De BortoliM, CiniselliC, et al. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol. 2014;25(2):352–357. doi:10.1093/annonc/mdt49024306042
   PubMed Web of Science ®Google Scholar
• SangokoyaC, DossJF, ChiJ-T. Iron-responsive miR-485-3p regulates cellular iron homeostasis by targeting ferroportin. PLoS Genet. 2013;9(4):e1003408. doi:10.1371/journal.pgen.100340823593016
   PubMed Web of Science ®Google Scholar
• MillerLD, CoffmanLG, ChouJW, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011;71(21):6728–6737. doi:10.1158/0008-5472.CAN-11-187021875943
   PubMed Web of Science ®Google Scholar
• ChenY, ZhangS, WangX, et al. Disordered signaling governing ferroportin transcription favors breast cancer growth. Cell Signal. 2015;27(1):168–176. doi:10.1016/j.cellsig.2014.11.00225451081
   PubMed Web of Science ®Google Scholar
• YangX, ParkS-H, ChangH-C, et al. Sirtuin 2 regulates cellular iron homeostasis via deacetylation of transcription factor NRF2. J Clin Invest. 2017;127(4):1505–1516. doi:10.1172/JCI8857428287409
   PubMed Web of Science ®Google Scholar
• JeongSM, LeeJ, FinleyL, et al. SIRT3 regulates cellular iron metabolism and cancer growth by repressing iron regulatory protein 1. Oncogene. 2015;34(16):2115–2124. doi:10.1038/onc.2014.12424909164
   PubMed Web of Science ®Google Scholar
• XiongY, WangM, ZhaoJ, et al. Sirtuin 3: A Janus face in cancer. Int J Oncol. 2016;49(6):2227–2235. doi:10.3892/ijo.2016.376727840909
   PubMed Web of Science ®Google Scholar
• Torrens‐MasM, PonsDG, Sastre‐SerraJ, et al. SIRT3 silencing sensitizes breast cancer cells to cytotoxic treatments through an increment in ROS production. J Cell Biochem. 2017;118(2):397–406. doi:10.1002/jcb.2565327420645
   PubMed Web of Science ®Google Scholar
• DesoukiMM, DoubinskaiaI, GiusD, et al. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Hum Pathol. 2014;45(5):1071–1077. doi:10.1016/j.humpath.2014.01.00424746213
   PubMed Web of Science ®Google Scholar
• WangY-F, ZhangJ, SuY, et al. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat Commun. 2017;8(1):1–14.28232747
   PubMed Web of Science ®Google Scholar
• HabashyHO, PoweDG, StakaCM, et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat. 2010;119(2):283. doi:10.1007/s10549-009-0345-x19238537
   PubMed Web of Science ®Google Scholar
• HuC, YangK, LiM, et al. Lipocalin 2: a potential therapeutic target for breast cancer metastasis. Onco Targets Ther. 2018;11:8099. doi:10.2147/OTT.S18122330519052
   PubMed Web of Science ®Google Scholar
• JungM, MertensC, BauerR, et al. Lipocalin-2 and iron trafficking in the tumor microenvironment. Pharmacol Res. 2017;120:146–156. doi:10.1016/j.phrs.2017.03.01828342790
   PubMed Web of Science ®Google Scholar
• MertensC, MoraJ, ÖrenB, et al. Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment. Oncoimmunology. 2018;7(3):e1408751. doi:10.1080/2162402X.2017.140875129399416
   PubMed Web of Science ®Google Scholar
• SolaA, WeigertA, JungM, et al. Sphingosine‐1‐phosphate signalling induces the production of Lcn‐2 by macrophages to promote kidney regeneration. J Pathol. 2011;225(4):597–608. doi:10.1002/path.298222025214
   PubMed Web of Science ®Google Scholar
• JungM, ÖrenB, MoraJ, et al. Lipocalin 2 from macrophages stimulated by tumor cell–derived sphingosine 1-phosphate promotes lymphangiogenesis and tumor metastasis. Sci Signal. 2016;9(434):ra64–ra64. doi:10.1126/scisignal.aaf324127353364
   PubMed Web of Science ®Google Scholar
• YangJ, BielenbergDR, RodigSJ, et al. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci. 2009;106(10):3913–3918. doi:10.1073/pnas.081061710619237579
   PubMed Web of Science ®Google Scholar
• YanL, BorregaardN, KjeldsenL, et al. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL) modulation of MMP-9 activity by NGAL. J Biol Chem. 2001;276(40):37258–37265. doi:10.1074/jbc.M10608920011486009
   PubMed Web of Science ®Google Scholar
• ZhangC, ZhangF. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell. 2015;6(2):88–100. doi:10.1007/s13238-014-0119-z25476483
   PubMed Web of Science ®Google Scholar
• KautzL, MeynardD, MonnierA, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008;112(4):1503–1509. doi:10.1182/blood-2008-03-14335418539898
   PubMed Web of Science ®Google Scholar
• RuchalaP, NemethE. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014;35(3):155–161. doi:10.1016/j.tips.2014.01.00424552640
   PubMed Web of Science ®Google Scholar
• LangerAL, GinzburgYZ. Role of hepcidin‐ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammation. Hemodialysis Int. 2017;21:S37–S46. doi:10.1111/hdi.12543
   Web of Science ®Google Scholar
• CookeKS, HinkleB, Salimi-MoosaviH, et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood J Am Soc Hematol. 2013;122(17):3054–3061.
   Google Scholar
• Vadhan-RajS, AbonourR, GoldmanJW, et al. A first-in-human Phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017;10(1):73. doi:10.1186/s13045-017-0427-x28327200
   PubMed Web of Science ®Google Scholar
• SasuBJ, CookeKS, ArvedsonTL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115(17):3616–3624. doi:10.1182/blood-2009-09-24597720053755
   PubMed Web of Science ®Google Scholar
• WhiteJ. The regulation and expression of hepcidin in carcinogenesis as a result of iron overload disorders: an extended literature review. J Cancer Prev Curr Res. 2015;3(2):00077.
   Google Scholar
• KatsarouA, PantopoulosK. Hepcidin therapeutics. Pharmaceuticals. 2018;11(4):127. doi:10.3390/ph11040127
   Web of Science ®Google Scholar
• RossSL, BiswasK, RottmanJ, et al. Identification of antibody and small molecule antagonists of ferroportin-hepcidin interaction. Front Pharmacol. 2017;8:838. doi:10.3389/fphar.2017.0083829209212
   PubMed Web of Science ®Google Scholar
• PeyssonnauxC, ZinkernagelAS, SchuepbachRA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007;117(7):1926–1932. doi:10.1172/JCI3137017557118
   PubMed Web of Science ®Google Scholar
• PurohitA, NewmanSP, ReedMJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002;4(2):1–5. doi:10.1186/bcr42511879551
   PubMed Web of Science ®Google Scholar
• JiangX-P, YangDC, ElliottRL, et al. Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells. Anticancer Res. 2011;31(9):2899–2906.21868536
   PubMed Web of Science ®Google Scholar
• HongD, KurzrockR, KimY, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;7(314):314ra185–314ra185. doi:10.1126/scitranslmed.aac5272
   PubMed Web of Science ®Google Scholar
• MeyerDM, JessonMI, LiX, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010;7(1):1–12. doi:10.1186/1476-9255-7-41
   Google Scholar
• PemmarajuN, KantarjianH, KadiaT, et al. A phase I/II study of the Janus kinase (JAK) 1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(3):171–176. doi:10.1016/j.clml.2014.08.00325441108
   PubMed Web of Science ®Google Scholar
• BoseP, VerstovsekS. JAK2 inhibitors for myeloproliferative neoplasms: what is next?Blood J Am Soc Hematol. 2017;130(2):115–125.
   Google Scholar
• PoliM, GirelliD, CampostriniN, et al. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood J Am Soc Hematol. 2011;117(3):997–1004.
   Google Scholar
• PoliM, AspertiM, NaggiA, et al. Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood J Am Soc Hematol. 2014;123(10):1564–1573.
   Google Scholar